TGFB1 and neoplasm: Despite this, evidence from patient samples and PDAC mice models revealed a metabolic trigger of the autocrine TGFβ signaling, the EMT, and thereby, of increased tumor aggressiveness, when cholesterol biosynthesis is reduced (e.g., by pharmacologic treatment with statins), which ultimately promotes a squamous phenotype associated with poorer patient outcomes [68].